29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
In a much-anticipated move, the United States Department of Labor ("DOL") announced yesterday the fi...
Read More >
Sunday’s release of a long-awaited Labor Department final rule on joint employment spells trouble f...
Read More >
The Ballard Spahr Zoning and Land Use Team is continuing to monitor all aspects of the Philadelphia ...
Read More >
Businesses at different levels in the supply chain of a product choose to merge (“vertical mergers,...
Read More >
In his 2016 presidential campaign, Donald Trump frequently expressed populist themes, rhetorically c...
Read More >
New infrastructure projects will be an important part of Canada's recovery from the COVID-19 crisis,...
Read More >